Taysha Gene Therapies Inc (TSHA) Stock Analysis

Taysha Gene Therapies Inc (TSHA) is a publicly traded company in the HEALTHCARE sector. It trades at $5.69, carries a market capitalization of $1.72B. This page summarizes the public market data, fundamentals, and frequently asked questions for TSHA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Taysha Gene Therapies Inc currently has a Bullish sentiment score of 0.19.

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a leading gene therapy company based in Dallas, Texas, specializing in the development and commercialization of adeno-associated virus-based therapies aimed at treating monogenic diseases affecting the central nervous system. With a robust pipeline of innovative therapeutics, Taysha is committed to addressing unmet medical needs in the neurology space, leveraging its proprietary gene delivery platform to advance potentially transformative treatment options. The ...

GNG Research Analysis

GNG Research scores Taysha Gene Therapies Inc (TSHA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TSHA.

Frequently Asked Questions

Does TSHA pay dividends?

Taysha Gene Therapies Inc (TSHA) does not currently pay a regular dividend.

What is TSHA's market cap?

Taysha Gene Therapies Inc (TSHA) has a market capitalization of $1.72B with a current stock price of $5.69.